{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T13:59:17Z","timestamp":1770040757650,"version":"3.49.0"},"reference-count":118,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T00:00:00Z","timestamp":1694390400000},"content-version":"vor","delay-in-days":4332,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jpain.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pain"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1016\/j.jpain.2011.06.009","type":"journal-article","created":{"date-parts":[[2011,9,28]],"date-time":"2011-09-28T22:25:20Z","timestamp":1317248720000},"page":"1113-1129","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Gout: Current Insights and Future Perspectives"],"prefix":"10.1016","volume":"12","author":[{"given":"Howard S.","family":"Smith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna","family":"Bracken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua M.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpain.2011.06.009_bib1","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/art.1780220521","article-title":"Definitive diagnosis of gout by identification for urate crystals in asymptomatic metatarsophalangeal joints","volume":"22","author":"Agudelo","year":"1979","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jpain.2011.06.009_bib2","first-page":"1422","article-title":"Ketoprofen versus indomethacin in patients with acute gouty arthritis: A multicenter, double blind comparative study","volume":"15","author":"Altman","year":"1988","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jpain.2011.06.009_bib3","doi-asserted-by":"crossref","unstructured":"Anderson A, Singh JA: Pegloticase for chronic gout. Cochrane Database Syst Rev (3): CD008335, 2010","DOI":"10.1002\/14651858.CD008335.pub2"},{"key":"10.1016\/j.jpain.2011.06.009_bib4","doi-asserted-by":"crossref","first-page":"3632","DOI":"10.1002\/art.23993","article-title":"Resolution of gouty tophi after twelve weeks of pegloticase treatment","volume":"58","author":"Baraf","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jpain.2011.06.009_bib5","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/BOR.0b013e3282f54d03","article-title":"We can make gout management more successful now","volume":"20","author":"Becker","year":"2008","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.jpain.2011.06.009_bib6","first-page":"495","article-title":"Gout with superactive phosphoribosylpyrophosphate synthetase due to increased enzyme catalytic rate","volume":"99","author":"Becker","year":"1982","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.jpain.2011.06.009_bib7","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3899\/jrheum.071229","article-title":"Quality of life and disability in patients with treatment-failure gout","volume":"36","author":"Becker","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jpain.2011.06.009_bib8","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpain.2011.06.009_bib9","first-page":"2429","article-title":"Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis","volume":"31","author":"Borstad","year":"2004","journal-title":"J Rheumatol"},{"issue":"Suppl 15","key":"10.1016\/j.jpain.2011.06.009_bib10","first-page":"S459","article-title":"Clinical, humanistic, and economic outcomes of gout","volume":"11","author":"Brixner","year":"2005","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.jpain.2011.06.009_bib11","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0140-6736(10)60665-4","article-title":"Gout therapeutics: New drugs for an old disease","volume":"377","author":"Burns","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jpain.2011.06.009_bib12","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/MEJ.0b013e32832a083f","article-title":"Oral prednisolone is more cost-effective than oral indomethacin for treating patients with acute gout-like arthritis","volume":"16","author":"Cattermole","year":"2009","journal-title":"Eur J Emerg Med"},{"key":"10.1016\/j.jpain.2011.06.009_bib13","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11926-009-0019-z","article-title":"A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout","volume":"11","author":"Chao","year":"2009","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.jpain.2011.06.009_bib14","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0149-2918(04)90035-5","article-title":"A single-blind, randomized, controlled trial to assess the efficacy and tolerability of rofecoxib, diclofenac sodium, and meloxicam in patients with acute gouty arthritis","volume":"26","author":"Cheng","year":"2004","journal-title":"Clin Ther"},{"key":"10.1016\/j.jpain.2011.06.009_bib15","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1136\/ard.2008.099713","article-title":"Dual energy computed tomography in tophaceous gout","volume":"68","author":"Choi","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jpain.2011.06.009_bib16","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1056\/NEJMoa035700","article-title":"Purine-rich foods, dairy and protein intake, and the risk of gout in men","volume":"350","author":"Choi","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpain.2011.06.009_bib17","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S0140-6736(04)16000-5","article-title":"Alcohol intake and risk of incident gout in men: A prospective study","volume":"363","author":"Choi","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jpain.2011.06.009_bib18","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/bmj.39449.819271.BE","article-title":"Soft drinks, fructose consumption, and the risk of gout in men: Prospective cohort study","volume":"336","author":"Choi","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.jpain.2011.06.009_bib19","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1001\/archinternmed.2008.606","article-title":"Vitamin C intake and the risk of gout in men: A prospective study","volume":"169","author":"Choi","year":"2009","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jpain.2011.06.009_bib20","doi-asserted-by":"crossref","first-page":"499","DOI":"10.7326\/0003-4819-143-7-200510040-00009","article-title":"Pathogenesis of gout","volume":"143","author":"Choi","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jpain.2011.06.009_bib21","series-title":"Clinical and Laboratory Features, in Primer on the Rheumatic Diseases","year":"2007"},{"key":"10.1016\/j.jpain.2011.06.009_bib22","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1476-5381.2008.00065.x","article-title":"Allopurinol for pain relief: More than just crystal clearance?","volume":"156","author":"Connor","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jpain.2011.06.009_bib23","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1203\/00006450-197205000-00004","article-title":"Diagnosis and treatment of the Lesch-Nyhan syndrome","volume":"6","author":"Crawhall","year":"1972","journal-title":"Pediatr Res"},{"key":"10.1016\/j.jpain.2011.06.009_bib24","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1681\/ASN.V12112348","article-title":"Familial juvenile hyperuricemic nephropathy and autosomal dominant medullary cystic kidney disease type 2: Two facets of the same disease?","volume":"12","author":"Dahan","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jpain.2011.06.009_bib25","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2165\/00003088-200746080-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol","volume":"46","author":"Day","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jpain.2011.06.009_bib26","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00256-010-1008-z","article-title":"Ultrasound features of tophi in chronic tophaceous gout","volume":"40","author":"De \u00c1vila Fernandes","year":"2011","journal-title":"Skeletal Radiol"},{"key":"10.1016\/j.jpain.2011.06.009_bib27","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1016\/S0140-6736(08)61343-4","article-title":"Association of three genetic loci with uric acid concentration and risk of gout: A genome-wide association study","volume":"372","author":"Dehghan","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jpain.2011.06.009_bib28","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3111\/13696998.2010.540874","article-title":"Work productivity loss due to flares in patients with chronic gout refractory to conventional therapy","volume":"14","author":"Edwards","year":"2011","journal-title":"J Med Econ"},{"key":"10.1016\/j.jpain.2011.06.009_bib29","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/j.clinthera.2009.11.033","article-title":"Febuxostat: A selective xanthine-oxidase\/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout","volume":"31","author":"Ernst","year":"2009","journal-title":"Clin Ther"},{"key":"10.1016\/j.jpain.2011.06.009_bib30","first-page":"37","article-title":"Febuxostat (Uloric) for chronic treatment of gout","volume":"51","year":"2009","journal-title":"Med Lett Drugs Ther"},{"key":"10.1016\/j.jpain.2011.06.009_bib31","first-page":"2285","article-title":"Treatment of acute attacks of gout with a small dose of intraarticular triamcinolone acetonide","volume":"26","author":"Fern\u00e1ndez","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jpain.2011.06.009_bib32","first-page":"2","article-title":"Ultrasound imaging for the rheumatologist. XXV. Sonographic assessment of the knee in patients with gout and calcium pyrophosphate deposition disease","volume":"28","author":"Filippucci","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jpain.2011.06.009_bib33","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3109\/15563650.2010.495348","article-title":"Colchicine poisoning: The dark side of an ancient drug","volume":"48","author":"Finkelstein","year":"2010","journal-title":"Clin Toxicol (Phila)"},{"key":"10.1016\/j.jpain.2011.06.009_bib34","unstructured":"Fitz-Patrick D, Drummond W, Pappas J, Hollister AS: Effects of a Purine Nucleoside Phosphorylase Inhibitor, BCX4208, on the Serum Uric Acid Concentrations in Patients with Gout. American College of Rheumatology Annual Meeting, Atlanta, Georgia; Abstract 150, November 2010"},{"key":"10.1016\/j.jpain.2011.06.009_bib35","article-title":"Acute gout management during hospitalisation: A need for a protocol","author":"Gnanenthiran","year":"2010","journal-title":"Intern Med J"},{"key":"10.1016\/j.jpain.2011.06.009_bib36","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1749-6632.2009.05159.x","article-title":"Blocking interleukin-1 in rheumatic diseases. Its initial disappointments and recent successes in the treatment of autoinflammatory diseases","volume":"1182","author":"Goldbach-Mansky","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jpain.2011.06.009_bib37","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/RLI.0b013e318157a144","article-title":"Dual energy CT characterization of urinary calculi: Initial in\u00a0vitro and clinical experience","volume":"43","author":"Graser","year":"2008","journal-title":"Invest Radiol"},{"key":"10.1016\/j.jpain.2011.06.009_bib38","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.semarthrit.2006.08.001","article-title":"\u201cCrystal clear\u201d\u2014sonographic assessment of gout and calcium pyrophosphate deposition disease","volume":"36","author":"Grassi","year":"2006","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jpain.2011.06.009_bib39","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.amjmed.2009.05.026","article-title":"The dynamics of chronic gout treatment: Medication gaps and return to therapy","volume":"123","author":"Harrold","year":"2010","journal-title":"Am J Med"},{"key":"10.1016\/j.jpain.2011.06.009_bib40","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.R110.135491","article-title":"The genetic and molecular basis of inflammasome-mediated disease","author":"Hoffman","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jpain.2011.06.009_bib41","first-page":"1341","article-title":"Recent diuretic use and the risk of recurrent gout attacks: The online case-crossover gout study","volume":"33","author":"Hunter","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jpain.2011.06.009_bib42","doi-asserted-by":"crossref","DOI":"10.1007\/s10067-010-1457-8","article-title":"International position paper on febuxostat","author":"Jansen","year":"2010","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jpain.2011.06.009_bib43","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1001\/archinternmed.2010.196","article-title":"A diagnostic rule for acute gouty arthritis in primary care without joint fluid analysis","volume":"170","author":"Janssens","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jpain.2011.06.009_bib44","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1136\/ard.2009.123687","article-title":"Limited validity of the American College of Rheumatology criteria for classifying patients with gout in primary care","volume":"69","author":"Janssens","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jpain.2011.06.009_bib45","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1016\/S0140-6736(08)60799-0","article-title":"Use of oral prednisolone or naproxen for the treatment of gout arthritis: A double-blind, randomised equivalence trial","volume":"371","author":"Janssens","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jpain.2011.06.009_bib46","doi-asserted-by":"crossref","unstructured":"Janssens HJ, Lucassen PL, Van de Laar FA, Janssen M, Van de Lisdonk EH: Systemic corticosteroids for acute gout. Cochrane Database Syst Rev (2): CD005521, 2008","DOI":"10.1002\/14651858.CD005521.pub2"},{"key":"10.1016\/j.jpain.2011.06.009_bib47","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0304-3959(01)00435-3","article-title":"Analgesic and anti-inflammatory effects of A-286501, a novel orally active adenosine kinase inhibitor","volume":"96","author":"Jarvis","year":"2002","journal-title":"Pain"},{"key":"10.1016\/j.jpain.2011.06.009_bib48","first-page":"1494","article-title":"Effect of balneotherapy in Ciechocinek Spa on the occurrence of gouty attacks and the symptoms of chronic gouty arthropathy (observations of 112 cures)","volume":"J11","author":"Kawenoki-Minc","year":"1972","journal-title":"Pol Med"},{"key":"10.1016\/j.jpain.2011.06.009_bib49","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/rheumatology\/keq346","article-title":"Long-term therapy for chronic gout results in clinically important improvements in the health-related quality of life: Short form-36 is responsive to change in chronic gout","volume":"50","author":"Khanna","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jpain.2011.06.009_bib50","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/ker023","article-title":"Minimally important differences of the gout impact scale in a randomized controlled trial","author":"Khanna","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jpain.2011.06.009_bib51","doi-asserted-by":"crossref","first-page":"821","DOI":"10.2165\/00003088-200645080-00005","article-title":"Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects","volume":"45","author":"Khosravan","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jpain.2011.06.009_bib52","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/RHU.0b013e3181e92c38","article-title":"Tophaceous gout of the knee: Revisiting MRI patterns in 30 patients","volume":"16","author":"Ko","year":"2010","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.jpain.2011.06.009_bib53","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.23176","article-title":"Estimates of the prevalence of arthritis and other rheumatic conditions in the United States","volume":"58","author":"Lawrence","year":"2008","journal-title":"Part II. Arthritis Rheum"},{"key":"10.1016\/j.jpain.2011.06.009_bib54","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s11926-007-0040-z","article-title":"Uric acid nephrolithiasis","volume":"9","author":"Liebman","year":"2007","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.jpain.2011.06.009_bib55","first-page":"67","article-title":"Clinical application of acupuncture and moxibustion to the treatment of gouty arthritis and analysis on their therapeutic effects","volume":"34","author":"Lin","year":"2009","journal-title":"Zhen Ci Yan Jiu"},{"key":"10.1016\/j.jpain.2011.06.009_bib56","first-page":"659","article-title":"Observation on therapeutic effect of electroacupuncture combined with local blocking therapy on acute gouty arthritis","volume":"28","author":"Liu","year":"2008","journal-title":"Zhongguo Zhen Jiu"},{"key":"10.1016\/j.jpain.2011.06.009_bib57","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1185\/03007999109111513","article-title":"Effectiveness of etodolac (\u2018Lodine\u2019) compared with naproxen in patients with acute gout","volume":"12","author":"Maccagno","year":"1991","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jpain.2011.06.009_bib58","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.annemergmed.2006.11.014","article-title":"Comparison of oral prednisolone\/paracetamol and oral indomethacin\/paracetamol combination therapy in the treatment of acute goutlike arthritis: A double-blind, randomized, controlled trial","volume":"49","author":"Man","year":"2007","journal-title":"Ann Emerg Med"},{"issue":"Suppl 2","key":"10.1016\/j.jpain.2011.06.009_bib59","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.3949\/ccjm.77.s2.01","article-title":"Preventing and treating acute gout attacks across the clinical spectrum: A roundtable discussion","volume":"77","author":"Mandell","year":"2010","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.jpain.2011.06.009_bib60","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/eji.200940168","article-title":"Signaling by ROS drives inflammasome activation","volume":"40","author":"Martinon","year":"2010","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jpain.2011.06.009_bib61","unstructured":"The Medical Letter on Drugs and Therapeutics. February 7, 53:9\u201312, 2011"},{"key":"10.1016\/j.jpain.2011.06.009_bib62","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0033-8389(03)00158-1","article-title":"Gout: A clinical and radiologic review","volume":"42","author":"Monu","year":"2004","journal-title":"Radiol Clin North Am"},{"key":"10.1016\/j.jpain.2011.06.009_bib63","first-page":"1762","article-title":"Prophylactic effect of highly selective COX-2 inhibition in acute monosodium urate crystal induced inflammation in the rat subcutaneous air pouch","volume":"32","author":"Nalbant","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jpain.2011.06.009_bib64","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMcp1001124","article-title":"Clinical practice. Gout","volume":"364","author":"Neogi","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpain.2011.06.009_bib65","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/BOR.0b013e3283361ac0","article-title":"Unusual clinical presentations of gout","volume":"22","author":"Ning","year":"2010","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.jpain.2011.06.009_bib66","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.cbi.2010.12.004","article-title":"3,5,2\u2032,4\u2032-Tetrahydroxychalcone, a new non-purine xanthine oxidase inhibitor","volume":"189","author":"Niu","year":"2011","journal-title":"Chem Biol Interact"},{"key":"10.1016\/j.jpain.2011.06.009_bib67","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/ar1906","article-title":"A concise history of gout and hyperuricemia and their treatment","volume":"8","author":"Nuki","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jpain.2011.06.009_bib68","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/BOR.0b013e328335eee3","article-title":"A roadmap for education to improve the quality of care in gout","volume":"22","author":"Ogdie","year":"2010","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.jpain.2011.06.009_bib69","doi-asserted-by":"crossref","first-page":"756","DOI":"10.7326\/0003-4819-131-10-199911160-00007","article-title":"Synovial fluid analysis for diagnosis of intercritical gout","volume":"131","author":"Pascual","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jpain.2011.06.009_bib70","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.3899\/jrheum.091385","article-title":"Diagnosis of chronic gout: Evaluating the american college of rheumatology proposal, European league against rheumatism recommendations, and clinical judgment","volume":"37","author":"Pel\u00e1ez-Ballestas","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jpain.2011.06.009_bib71","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1523-1755.2004.00774.x","article-title":"Homozygosity for uromodulin disorders: FJHN and MCKD-type 2","volume":"66","author":"Rezende-Lima","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.jpain.2011.06.009_bib72","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S0140-6736(09)60883-7","article-title":"Gout","volume":"375","author":"Richette","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jpain.2011.06.009_bib73","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1001\/jama.289.21.2857","article-title":"Gout","volume":"289","author":"Rott","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.jpain.2011.06.009_bib74","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/art.20007","article-title":"Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: A randomized controlled trial","volume":"50","author":"Rubin","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jpain.2011.06.009_bib75","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S0025-6196(12)60443-1","article-title":"Mitral stenosis associated with valvular tophi","volume":"59","author":"Scalapino","year":"1984","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jpain.2011.06.009_bib76","first-page":"2256","article-title":"Serum urate during bouts of acute gouty arthritis","volume":"24","author":"Schlesinger","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jpain.2011.06.009_bib77","first-page":"331","article-title":"Local ice therapy during bouts of acute gouty arthritis","volume":"29","author":"Schlesinger","year":"2002","journal-title":"J Rheumatol"},{"issue":"Suppl 15","key":"10.1016\/j.jpain.2011.06.009_bib78","first-page":"S443","article-title":"Diagnosis of gout: Clinical, laboratory, and radiologic findings","volume":"11","author":"Schlesinger","year":"2005","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.jpain.2011.06.009_bib79","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/nrd3349","article-title":"Pegloticase","volume":"10","author":"Schlesinger","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jpain.2011.06.009_bib80","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1476-5381.2008.00025.x","article-title":"Antinociceptive properties of the xanthine oxidase inhibitor allopurinol in mice: Role of adenosine A1 receptors","volume":"156","author":"Schmidt","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jpain.2011.06.009_bib81","unstructured":"Schorn C, Frey B, Janko C, Schett G, Herrmann M: The NALP3 Inflammasome Is Activated by Sodium Overload and Water Influx in Gouty Arthritis. American College of Rheumatology Annual Meeting; Atlanta, Georgia; Abstract 2150, November 2010"},{"key":"10.1016\/j.jpain.2011.06.009_bib82","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/art.1780290610","article-title":"Reproducibility of synovial fluid analyses: A study among four laboratories","volume":"29","author":"Schumacher","year":"1986","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jpain.2011.06.009_bib83","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1136\/bmj.324.7352.1488","article-title":"Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis","volume":"324","author":"Schumacher","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.jpain.2011.06.009_bib84","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","article-title":"Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: A 28-week, phase III, randomized, double-blind, parallel-group trial","volume":"59","author":"Schumacher","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jpain.2011.06.009_bib85","unstructured":"Schumacher HR, Berger M, Li-Yu J, Perez-Ruiz F, Burgos Vargas R, Li C: Efficacy and Tolerability of Celecoxib in the Treatment of Moderate to Extreme Pain Associated with Acute Gouty Arthritis: A Randomized Controlled Trial. American College of Rheumatology Annual Meeting; Atlanta, Georgia; Abstract 151, November 2010"},{"key":"10.1016\/j.jpain.2011.06.009_bib86","doi-asserted-by":"crossref","first-page":"8326","DOI":"10.1073\/pnas.87.21.8326","article-title":"Fructose-induced aberration of metabolism in familial gout identified by 31P magnetic resonance spectroscopy","volume":"87","author":"Seegmiller","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jpain.2011.06.009_bib87","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S0196-0644(95)70037-4","article-title":"Randomized doubleblind comparison of the analgesic efficacy of intramuscular ketorolac and oral indomethacin in the treatment of acute gouty arthritis","volume":"26","author":"Shrestha","year":"1995","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.jpain.2011.06.009_bib88","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1097\/RHU.0b013e3181be2423","article-title":"IL-1 inhibition with anakinra in a patient with refractory gout","volume":"15","author":"Singh","year":"2009","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.jpain.2011.06.009_bib89","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s11926-009-0022-4","article-title":"Quality of life and quality of care for patients with gout","volume":"11","author":"Singh","year":"2009","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.jpain.2011.06.009_bib90","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1136\/ard.2008.092619","article-title":"Opportunities for improving medication use and monitoring in gout","volume":"68","author":"Singh","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jpain.2011.06.009_bib91","doi-asserted-by":"crossref","first-page":"R28","DOI":"10.1186\/ar2143","article-title":"A pilot study of IL-1 inhibition by anakinra in acute gout","volume":"9","author":"So","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jpain.2011.06.009_bib92","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1002\/art.27600","article-title":"Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study","volume":"62","author":"So","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jpain.2011.06.009_bib93","doi-asserted-by":"crossref","unstructured":"So A, De Meulemeester M, Pikhlak A, Y\u00fccel1 AE, Arulmani U, Richard D, Stricker K, Ferreira A, Murphy V, Sallstig P, Schlesinger N: Rapid Improvement in Health-Related Quality of Life (HRQoL) in Gouty Arthritis Patients Treated with Canakinumab (ACZ885) Compared to Triamcinolone Acetonide. American College of Rheumatology Annual Meeting; Atlanta, Georgia; Abstract 1423, November 2010","DOI":"10.1093\/rheumatology\/ker027"},{"key":"10.1016\/j.jpain.2011.06.009_bib94","doi-asserted-by":"crossref","first-page":"7993","DOI":"10.4049\/jimmunol.179.12.7993","article-title":"COPs and POPs: Modulators of inflammasome activity","volume":"179","author":"Stehlik","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.jpain.2011.06.009_bib95","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2165\/00003088-200847020-00004","article-title":"Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects","volume":"47","author":"Stocker","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jpain.2011.06.009_bib96","doi-asserted-by":"crossref","DOI":"10.3899\/jrheum.101160","article-title":"Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout","author":"Stocker","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jpain.2011.06.009_bib97","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/art.22403","article-title":"Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout","volume":"56","author":"Sundy","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jpain.2011.06.009_bib98","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1002\/art.24201","article-title":"Gout management: Let\u2019s get it right this time","volume":"59","author":"Sundy","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"Suppl","key":"10.1016\/j.jpain.2011.06.009_bib99","first-page":"S400","article-title":"Efficacy and safety of intravenous (IV) pegloticase (PGL) in subjects with treatment failure gout (TFG): Phase 3 results from GOUT1 and GOUT2 [Abstract]","volume":"58","author":"Sundy","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jpain.2011.06.009_bib100","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1002\/art.23810","article-title":"Pegloticase Phase 2 Study Investigators: Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: Results of a phase II randomized study","volume":"58","author":"Sundy","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jpain.2011.06.009_bib101","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1093\/rheumatology\/kel071","article-title":"Effectiveness of interventions for the treatment of acute and prevention of recurrent gout\u2014a systematic review","volume":"45","author":"Sutaria","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jpain.2011.06.009_bib102","doi-asserted-by":"crossref","first-page":"9789","DOI":"10.1073\/pnas.1000779107","article-title":"Altered redox state of monocytes from cryopyrin-associated periodic syndromes causes accelerated IL-1beta secretion","volume":"107","author":"Tassi","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jpain.2011.06.009_bib103","first-page":"1955","article-title":"Learning how and when to employ uricase as bridge therapy in refractory gout","volume":"34","author":"Terkeltaub","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jpain.2011.06.009_bib104","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.semarthrit.2008.08.006","article-title":"Colchicine Update","volume":"38","author":"Terkeltaub","year":"2008","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jpain.2011.06.009_bib105","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1136\/ard.2009.108936","article-title":"The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: Results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study","volume":"68","author":"Terkeltaub","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jpain.2011.06.009_bib106","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrrheum.2009.236","article-title":"Update on gout: New therapeutic strategies and options","volume":"6","author":"Terkeltaub","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jpain.2011.06.009_bib107","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.27327","article-title":"High vs low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study","volume":"62","author":"Terkeltaub","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jpain.2011.06.009_bib108","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/nri2725","article-title":"NLRP3 inflammasome activation: The convergence of multiple signalling pathways on ROS production","volume":"10","author":"Tschopp","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jpain.2011.06.009_bib109","unstructured":"US Food and Drug Administration. FDA labeling information\u2014Krystexxa (pegloticase). FDA website [online]. Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/125293s0000lbl.pdf. Accessed August 11, 2011"},{"key":"10.1016\/j.jpain.2011.06.009_bib110","unstructured":"US FDA. Rheumatology information: Non-selective nonsteroidal anti-inflammatory drugs [online]. Available at: http:\/\/www.fda.gov\/Drugs\/ResourcesForYou\/HealthProfessionals\/ucm106979.htm. Accessed July 2, 2010"},{"key":"10.1016\/j.jpain.2011.06.009_bib111","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0090-4295(01)01506-0","article-title":"Quality-of-life impact of lower urinary tract symptom severity: Results from the Health Professionals Follow-up Study","volume":"59","author":"Welch","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.jpain.2011.06.009_bib112","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1016\/j.clinthera.2011.01.008","article-title":"Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: Analysis of data from three phase III trials","volume":"32","author":"Wortmann","year":"2010","journal-title":"Clin Ther"},{"key":"10.1016\/j.jpain.2011.06.009_bib113","unstructured":"Yang X, Dick R, Borges V, Yazdani N, Green A, Manhard K, Quart B, Yeh L: Evaluation of Drug-Drug Interaction Potential between RDEA594, Alloputinal and Febuxostat in Preclinical Species. ACR-ARHP Annual Scientific Meeting; Philadelphia, PA; Poster #1102, October 2009"},{"key":"10.1016\/j.jpain.2011.06.009_bib114","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.2165\/11205470-000000000-00000","article-title":"Oral colchicine (Colcrys): In the treatment and prophylaxis of gout","volume":"70","author":"Yang","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.jpain.2011.06.009_bib115","unstructured":"Yeh L, Hingorani V, Manhard K, Borges V, Nguyen M, Tieu K, Quart B: Safety and uric acid lowering effect in humans following multiple doses of RDEA806, a novel prodrug for the potential treatment of hyperuricemia. Annual European Congress of Rheumatology EULAR; Paris, France; Poster #THU0356, June 2008"},{"key":"10.1016\/j.jpain.2011.06.009_bib116","unstructured":"Yeh L, Kerr B, Shen Z, Hingorani V, Sheedy B, Nguyen M, Polvent L, Manhard K, Quart B: Safety, pharmacokinetics, and serum uric acid lowering effect of RDEA594, a novel uricosuric agent, in healthy volunteers. Annual European Congress of Rheumatology EULAR; Copenhagen, Denmark; Poster THU0451, June 2009"},{"key":"10.1016\/j.jpain.2011.06.009_bib117","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","article-title":"EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT)","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jpain.2011.06.009_bib118","doi-asserted-by":"crossref","first-page":"800.e13","DOI":"10.1016\/j.amjmed.2006.01.020","article-title":"Alcohol consumption as a trigger of recurrent gout attacks","volume":"119","author":"Zhang","year":"2006","journal-title":"Am J Med"}],"container-title":["The Journal of Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526590011006638?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526590011006638?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:52:43Z","timestamp":1761508363000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526590011006638"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":118,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S1526590011006638"],"URL":"https:\/\/doi.org\/10.1016\/j.jpain.2011.06.009","relation":{},"ISSN":["1526-5900"],"issn-type":[{"value":"1526-5900","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gout: Current Insights and Future Perspectives","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pain","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpain.2011.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 American Pain Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}